Pfizer released a new respiratory syncytial virus (RSV) vaccine TV commercial, titled “Your Moments Are Worth Protecting: Celebration” as part of its ongoing campaign to raise awareness about the importance of vaccination against RSV.
In the 30-second commercial, Pfizer showcases a series of celebratory moments, appearing to be taken by everyday people on their cell phones. These moments include birthdays, family gatherings and people just out and about having a good time engaging in various activities like sledding and playing in the park.
The voiceover accompanying the scenes emphasizes the importance of protecting special times with friends and family.
The voiceover says that, “From celebration moments to joy ride moments. Your moments are worth protecting against RSV.”
The message reinforces that these moments, both big and small, deserve to be safeguarded, inspiring viewers to consider how they can actively protect their health.
The commercial talks about RSV being a “highly contagious virus” and that people 60 years of age and older have a higher risk of being hospitalized from RSV, making vaccination against the virus important.
“You know how to protect against COVID and flu so ask your pharmacist or doctor about scheduling an RSV vaccine, too.”
“Because moments like these matter,” the commercial ends off saying.
RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can lead to severe illness in young children, older adults and those with weakened immune systems. It is highly contagious and spreads through respiratory droplets.
According to the Centers for Disease Control and Prevention (CDC), while exact infection numbers are challenging to determine due to underreporting and the mild nature of many cases, RSV causes approximately 2.1 million outpatient visits among children under five years old and results in 58,000 to 80,000 hospitalizations in this age group. Among adults aged 60 and older, RSV accounts for about 100,000 to 160,000 hospitalizations annually.
Related: Arexvy Shows Strong Efficacy Over Three RSV Seasons in New Phase III Data
Arexvy Versus Abrysvo: How Do The RSV Vaccines Compare?
The RSV vaccine TV commercial was released at the end of October to kick off flu season, which peaks between December and February. The season marks an increase in not just influenza, but also susceptibility to other respiratory viruses, including those that cause COVID-19 and RSV.
During this period, respiratory viruses spread more easily due to cooler temperatures and increased time spent indoors where transmission rates are higher.
Getting vaccinated each year is one of the most effective ways to prevent illness, particularly severe illness that could lead to hospitalization.
XTALKS WEBINAR: Solutions for Vaccine Innovation and Gene Therapy: Unlocking the Power of RNA
Live and On-Demand: Tuesday, December 17, 2024, at 9am EST (3pm CET/EU-Central)
Register for this free webinar to explore how next-generation RNA technologies can provide effective solutions for vaccine innovation and gene therapy.
Pfizer’s RSV vaccine Abrysvo was approved in May 2023, along with GSK’s Arexvy, which was approved earlier that same month. Moderna entered the RSV vaccine arena this year with the very first mRNA-based RSV vaccine.
In their first full year on the market, Arexvy led the right race, bringing in $1.5 billion compared to Abrysvo’s $890 million.
Despite expressing disappointment over its first-year performance, Pfizer scored a significant win last month with Abrysvo winning expanded US Food and Drug Administration (FDA) approval for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 18 to 59 who are at an increased risk of the disease. The approval is pivotal as it opens up the vaccine to the under-60 adult population.
On the other hand, Bloomberg recently reported that sales of Arexvy slowed down this year due to a decrease in demand, owing to US officials having prioritized access to adults aged 75 or over and more at-risk patients.
GSK said the continuing focus on COVID-19 vaccination also contributed to the decline in sales.
Both Abrysvo and Arexvy are approved for the prevention of RSV infection in adults 60 years of age and older. Abrysvo has an additional approval as a maternal vaccine for pregnant individuals (32 through 36 weeks gestational age) for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through six months of age.
Also last month, GSK shared late-stage trial data showing that across three RSV seasons, Arexvy has a cumulative efficacy against RSV-LRTD of 62.9, including 67.4 percent efficacy against severe RSV-LRTD.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN